Menu

Top Stories

Alpha-1 Foundation honors co-founder John W. Walsh with title of Director Emeritus

Alpha-1 Foundation honors co-founder  John W. Walsh with title of Director Emeritus
Wednesday, February 15, 2017
Alpha-1 Foundation Co-founder and visionary John W. Walsh has been named a Director Emeritus of the Board of Directors at the February 3, 2017 Board meeting. John W. Walsh “We have now passed the one-year anniversary of the accident January 20, 2016, when John was injured in a fall on an icy street in Washington, DC, and he is no longer playing an active role in the...
Divider

Scientists battle in court over lucrative patents for gene-editing technology

Tuesday, December 6, 2016
The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday. Emmanuelle Charpentier (left) and Jennifer Doudna A gene-editing technology called CRISPR-cas9 could be...
Divider

Congress passes 21st Century Cures Act, boosting research and easing drug approvals

Monday, December 5, 2016
Congress passed sweeping legislation Wednesday that boosts funding for medical research, eases the development and approval of experimental treatments, and reforms federal policy on mental health care. The 94 to 5 Senate vote Wednesday followed...
Divider

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

Friday, December 2, 2016
The medical journal The Lancet Respiratory Medicine on Thursday, Dec. 1, published findings of the RAPID Open Label Extension study of augmentation therapy for patients with emphysema and Alpha-1 Antitrypsin Deficiency. N. Gerard...
Divider

House overwhelmingly passes 21st Century Cures bill

Thursday, December 1, 2016
WASHINGTON — The House overwhelmingly passed a far-reaching measure on Wednesday to increase funding for research into cancer and other diseases, address weaknesses in the nation’s mental health systems and help combat the prescription...
Divider

Arrowhead halts clinical trial of Alpha-1 liver drug candidate, plans to move ahead with subcutaneous AAT program

Wednesday, November 30, 2016
Arrowhead Pharmaceuticals has halted clinical trials of several potential drug therapies using its EX1 delivery system, including ARC-AAT, which had been showing good results in clinical trials to treat Alpha-1 liver disease, the company said in a...
Divider

Investigational drug showed deep reduction of alpha-1 protein in healthy volunteers, Arrowhead reports at Liver Meeting

Monday, November 14, 2016
Arrowhead Pharmaceuticals, Inc. delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver disease associated with Alpha-1...
Divider

FDA, Alpha-1 Foundation discuss placebos, trial of augmentation after lung transplants

Friday, September 30, 2016
Just over one year ago, members of the Alpha-1 community traveled from around the country to Silver Spring, Maryland for a meeting with the U.S. Food and Drug Administration (FDA).   Charlotte Mattison, right, gives emotional testimony...
Divider

PPTA statement says plasma protein products are safe, not affected by Zika virus

Saturday, September 24, 2016
The Plasma Protein Therapeutics Association (PPTA) has issued a statement saying that the safety of plasma protein therapies is not affected by the Zika virus (ZIKV). "According to recommendations from health authorities, measures such as...
Divider

Arrowhead begins Phase 2 trial of possible Alpha-1 liver treatment

Tuesday, September 6, 2016
California-based Arrowhead Pharmaceuticals Inc. announced Tuesday that it has begun a Phase 2 clinical study of ARC-AAT, the company's potential treatment for liver disease in people with Alpha-1 Antitrypsin Deficiency (AATD), using the...
Divider

Kamada Phase 2 trial shows promising results for inhaled augmentation

Wednesday, August 31, 2016
Kamada has released the results of a clinical trial showing that inhaled augmentation produces higher levels of alpha-1 protein in the airways than traditional intravenous augmentation. Mark Brantly, MD The company says the study’s...
Divider

ATS editorial warns against unregulated stem cell “treatments”

Monday, August 22, 2016
The Annals of the ATS, a publication of the American Thoracic Society, has published an editorial that warns against the use of unregulated, expensive stem cell remedies to treat severe respiratory diseases. The editorial, written by Laertis...
Divider

UMass gets 5-year, $11 million research grant for Alpha-1 gene therapy

Thursday, August 11, 2016
The National Heart, Lung, and Blood Institute (NHLBI) has awarded an $11 million, five-year grant to the University of Massachusetts Medical School to study new approaches to Alpha-1 gene therapy. Members of the UMass program project grant...
Divider
123456

Article Search

Enter keywords in text box and click Search button for results.